Takeda Pharmaceutical Company Limited
4502
Kedudukan dalam Saham
#378
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise... Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Harga Saham
$40.26
Modal Pasaran
$64.06B
Perubahan (1 hari)
0.71%
Perubahan (1 tahun)
42.44%
Negara
JP
Perdagangan Takeda Pharmaceutical Company Limited (4502)
Kategori
Healthcare
Nisbah P/S bagi Takeda Pharmaceutical Company Limited (4502)
Nisbah P/S pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Takeda Pharmaceutical Company Limited, nisbah P/S semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/S syarikat ialah 0.
Sejarah nisbah P/S untuk Takeda Pharmaceutical Company Limited dari 2026 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
CH
|
|
| 7.06 | - |
IN
|
|
| - | - |
CN
|
